The dominos fell as expected in the non-alcoholic steatohepatitis (NASH) R&D space as Intercept Pharmaceuticals, Inc. announced late on 22 June that it had received a second complete response letter from the US Food and Drug Administration for obeticholic acid (OCA) in pre-cirrhotic NASH and told investors it was ending activity in the space. What remains unknown is how the fate of OCA, an FXR agonist, may read through to the rest of the burgeoning and varied NASH development race.
[Sidebar#SC148415]
